# Distant metastasis risk and prognosis in elderly gastric cancer patients after neoadjuvant chemotherapy and surgery

**Authors:** Jiarong Shang, Jin Zhu, Xia Zheng, Yujia Shao, Jun Qian, Yong Li, Ping Wang

PMC · DOI: 10.3389/fonc.2026.1757874 · Frontiers in Oncology · 2026-02-06

## TL;DR

This study identifies risk factors for distant metastasis and prognosis in elderly gastric cancer patients after chemotherapy and surgery, and develops tools to predict outcomes.

## Contribution

The study introduces two novel nomograms to predict postoperative distant metastasis and prognosis in elderly gastric cancer patients.

## Key findings

- 34.26% of elderly patients developed postoperative distant metastasis.
- Nomograms showed high predictive accuracy for metastasis and prognosis.
- Factors like N stage, CA19–9 levels, and tumor regression grade were significant predictors.

## Abstract

Gastric cancer imposes a heavy global health burden, and treatment evaluation in elderly patients is often more complex. Although NAC is standard for locally advanced gastric cancer (LAGC), benefits in the elderly are heterogeneous, postoperative distant metastasis (DM) is underexplored, and no nomogram specifically evaluates postoperative DM diagnosis and prognosis in elderly LAGC after NAC.

This study extracted data from patients over 70 years of age who were diagnosed with gastric adenocarcinoma and underwent neoadjuvant chemotherapy followed by curative gastrectomy between 2016 and 2022. Independent risk factors for postoperative distant metastasis following neoadjuvant chemotherapy were identified using univariate and multivariate logistic regression analyses, while independent prognostic factors were determined through univariate and multivariate Cox proportional hazards regression analyses. Subsequently, we developed two novel nomograms and evaluated their performance using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).

A total of 896 elderly gastric adenocarcinoma patients were enrolled, among whom 307 (34.26%) developed postoperative DM. Independent risk factors for DM included N stage, NAC-related adverse events, CA19–9 levels, NLR, tumor nodules, resection margin status, tumor regression grade, as well as intraoperative and postoperative chemotherapy. Among DM patients, independent prognostic predictors included CA72–4 levels, NLR, NAC-to-surgery interval, tumor regression grade, resection margin status, and postoperative chemotherapy. Both nomograms demonstrated high predictive accuracy, supported by ROC analysis, calibration curves, decision curve analysis, and Kaplan-Meier survival analysis in the training and validation sets.

The two nomograms show promise as effective tools for predicting the risk of postoperative distant metastasis and estimating personalized prognosis in elderly gastric cancer patients following neoadjuvant chemotherapy, thereby potentially informing clinical decision-making.

## Linked entities

- **Diseases:** gastric cancer (MONDO:0001056), gastric adenocarcinoma (MONDO:0005036)

## Full-text entities

- **Genes:** JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, MUC16 (mucin 16, cell surface associated) [NCBI Gene 94025] {aka CA125}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, mucin [NCBI Gene 100508689], TRG (T cell receptor gamma locus) [NCBI Gene 6965] {aka TCRG, TRG@}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, CEACAM3 (CEA cell adhesion molecule 3) [NCBI Gene 1084] {aka CD66D, CEA, CGM1, CGM1a, W264, W282}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}
- **Diseases:** impaired gastric emptying (MESH:D013272), toxicities (MESH:D064420), advanced (MESH:D020178), cerebral infarction (MESH:D002544), liver/peritoneal metastases (MESH:D010538), hypertension (MESH:D006973), malabsorption (MESH:D008286), malnutrition (MESH:D044342), death (MESH:D003643), colorectal cancer (MESH:D015179), OS (MESH:D011475), DM (MESH:D009362), frailty (MESH:D000073496), GC (MESH:D013274), diabetes mellitus (MESH:D003920), Tumor (MESH:D009369), coronary heart disease (MESH:D003327), immune-inflammation (MESH:D007249), sarcopenia (MESH:D055948), NLR (MESH:D015467)
- **Chemicals:** docetaxel (MESH:D000077143), XELOX (MESH:C519688), capecitabine (MESH:D000069287), DOX (MESH:D004317), CA19 (-), oxaliplatin (MESH:D000077150)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920236/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920236/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12920236/full.md

---
Source: https://tomesphere.com/paper/PMC12920236